Does OSIMERTINIB Cause Neoplasm progression? 132 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 132 reports of Neoplasm progression have been filed in association with OSIMERTINIB (TAGRISSO). This represents 0.5% of all adverse event reports for OSIMERTINIB.
132
Reports of Neoplasm progression with OSIMERTINIB
0.5%
of all OSIMERTINIB reports
16
Deaths
16
Hospitalizations
How Dangerous Is Neoplasm progression From OSIMERTINIB?
Of the 132 reports, 16 (12.1%) resulted in death, 16 (12.1%) required hospitalization, and 2 (1.5%) were considered life-threatening.
Is Neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OSIMERTINIB. However, 132 reports have been filed with the FAERS database.
What Other Side Effects Does OSIMERTINIB Cause?
Death (10,423)
Malignant neoplasm progression (2,920)
Diarrhoea (1,408)
Drug resistance (1,026)
Fatigue (819)
Rash (772)
Decreased appetite (706)
Drug ineffective (627)
Dyspnoea (621)
Nausea (610)
What Other Drugs Cause Neoplasm progression?
PALBOCICLIB (10,885)
SUNITINIB MALATE (1,920)
CYCLOPHOSPHAMIDE (1,588)
CARBOPLATIN (1,370)
AXITINIB (1,315)
DOXORUBICIN (1,276)
LETROZOLE (1,225)
PACLITAXEL (1,180)
CRIZOTINIB (1,161)
VINCRISTINE (1,106)
Which OSIMERTINIB Alternatives Have Lower Neoplasm progression Risk?
OSIMERTINIB vs OSPEMIFENE
OSIMERTINIB vs OSPHENA
OSIMERTINIB vs OVINE DIGOXIN IMMUNE FAB
OSIMERTINIB vs OXACILLIN
OSIMERTINIB vs OXALIPLATIN